These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10954064)

  • 21. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
    Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM
    J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluvoxamine attenuates panic induced by 35% CO2 challenge.
    Pols HJ; Hauzer RC; Meijer JA; Verburg K; Griez EJ
    J Clin Psychiatry; 1996 Nov; 57(11):539-42. PubMed ID: 8968304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suitable dose and duration of fluvoxamine administration to treat depression.
    Morishita S; Arita S
    Psychiatry Clin Neurosci; 2003 Apr; 57(2):177-81. PubMed ID: 12667164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Violent acts associated with fluvoxamine treatment.
    Okada F; Okajima K
    J Psychiatry Neurosci; 2001 Sep; 26(4):339-40. PubMed ID: 11590975
    [No Abstract]   [Full Text] [Related]  

  • 25. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
    Freeman EW; Rickels K; Sondheimer SJ
    J Clin Psychiatry; 1996; 57 Suppl 8():56-9; discussion 60. PubMed ID: 8698682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine.
    Miura M; Ohkubo T
    Xenobiotica; 2007 Feb; 37(2):169-79. PubMed ID: 17484519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
    Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
    Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.
    Palatnik A; Frolov K; Fux M; Benjamin J
    J Clin Psychopharmacol; 2001 Jun; 21(3):335-9. PubMed ID: 11386498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
    Fux M; Taub M; Zohar J
    Acta Psychiatr Scand; 1993 Oct; 88(4):235-7. PubMed ID: 8256637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy.
    Albers LJ; Ozdemir V; Marder SR; Raggi MA; Aravagiri M; Endrenyi L; Reist C
    J Clin Psychopharmacol; 2005 Apr; 25(2):170-4. PubMed ID: 15738749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
    Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
    J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
    Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
    J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of amitriptyline and carbamazepine on levomepromazine metabolism in human liver: an in vitro study.
    Wójcikowski J; Basińska A; Boksa J; Daniel WA
    Pharmacol Rep; 2014 Dec; 66(6):1122-6. PubMed ID: 25443744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.
    Goddard AW; Woods SW; Sholomskas DE; Goodman WK; Charney DS; Heninger GR
    Psychiatry Res; 1993 Aug; 48(2):119-33. PubMed ID: 8416022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application.
    Wójcikowski J; Basińska A; Daniel WA
    Biochem Pharmacol; 2014 Jul; 90(2):188-95. PubMed ID: 24841887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.
    Bagli M; Höflich G; Rao ML; Langer M; Baumann P; Kolbinger M; Barlage U; Kasper S; Möller HJ
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):646-52. PubMed ID: 8963481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
    Isohanni MH; Neuvonen PJ; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.